Patent Application
20240149040
Described and shown herein is a double lock sterile entry IV port and syringe interface system comprising a closed system that decreases or prevents patient exposure to bacteria when fluids are drawn up and injected in the field, at the bedside, or in the operating room.
The E. Wong U.S. Pat. No. 9,352,141 is directed to a system comprising a sterile entry IV port and a sterile entry syringe delivery mechanism. In U.S. Pat. No. 9,352,141 the IV port and syringe delivery mechanism can each have a cover over their respective entry or exit point. These covers keep the components of the IV port and/or syringe delivery mechanism sterile. The IV port and/or syringe delivery mechanism covers can each include a mechanism, such as a push mechanism, placed adjacent to the entry or exit point. When sufficient force is applied to this mechanism, the cover is raised away from the entry or exit point, allowing an IV port and syringe delivery mechanism to be joined using, for example, a single or double Luer Lock™ system. By enabling the cover to be raised without touching the entry or exit points, embodiments shown therein can prevent contamination of the IV port and syringe delivery mechanism. Further, the covers and/or the system comprising the covers can be reusable.
Prior clinical practice generally provides for the delivery of sterile solutions (e.g., drugs, fluids, and/or blood) by attaching uncapped Luer Lock™ syringes to uncovered Luer Lock™ needleless IV ports. In order to ensure a sterile environment, practitioners currently either swab the needleless IV port with alcohol or use single-use alcohol impregnated caps that are placed on the needleless IV port for about three minutes before delivery. This practice was found to not be adequate as patients continued to acquire healthcare-associated infections (HAI) because these prior practices were not always effective in ensuring a sterile environment.
Various other systems have been designed to aid medical professionals in the intravenous delivery of sterile solutions. Such systems are described, for example, in U.S. Pat. No. 6,003,556 to Brugger et al.; U.S. Pat. No. 5,881,774 to Utterberg; and U.S. Pat. No. 5,817,067 to Tsukada; as well as U.S. Pat. Pub. Nos. 2012/0238965 and 2010/0298783 to Chang. The figures and descriptions of U.S. Pat. No. 9,352,141 and all five of these patents and publications are incorporated herein in their entirety by reference. However, these systems were lacking in many regards. For instance, none of these systems ensures a sterile environment, and extra precautions such as those described above must therefore accompany their use.
Applicant's prior device shown and claimed in U.S. Pat. No. 9,352,141 addressed many of the prior potential contamination issues. The system shown and described therein is directed to a single or double-lock sterile entry intravenous port and syringe system. The system includes caps which can be hinged. These caps cover the entry points of the IV port and/or syringe and are intended to prevent the contamination of these areas. When ready for use a portion of each cap can be removed from the port by pressing on a mechanism spaced sufficiently away to prevent contamination by finger contact with the port opening. In turn, pressing on the mechanism causes the cap cover to raise, allowing access to the entry point of the IV port and/or syringe delivery mechanism. However, while that device was an improvement over prior devices it was still subject to bacterial contamination and the transmission of hospital-acquired infections.
The Double Lock Sterile Entry IV Port and Syringe Interface System disclosed herein is a closed system that further decreases or prevents patient exposure to bacteria when fluids are drawn up and injected in the field, at the bedside, or in the operating room. Along with potentially reducing or preventing HAIs, an additional application of this system is as a transfer device that decreases drug vapors and leakage in the administration of hazardous drugs such as chemotherapy. Throughout medical history there has been a continual effort to decrease or prevent the incidence of HAIs. As the science and technology of medical devices has improved, new medical devices have come onto the market that eliminate areas of potential exposure to bacterial contamination. This novel medical device is a next generation evolution in IV port and syringe connectors to prevent contamination of the fluids delivered or collected.
The improved sterile field contamination protection provided to combinations of an IV port and syringe, such as shown in U.S. Pat. No. 9,352,141, incorporated herein in its entirety by reference, and other prior devices, comprises a shrouded interface including food-grade silicone diaphragms provided as a covering along the flow path of fluids between the IV port and syringe. Benefits of the food-grade silicone diaphragm include high resistant to damage and degradation from extreme temperatures, it does not harden, crack, peel, crumble, dry out, rot or become brittle over time, it is lightweight, saves space, is easy to transport, is made from an abundant natural resource which is non-toxic and odorless, does not contain BPA, latex, lead, or phthalates, and it is considered to be a non-hazardous waste. Due to its resiliency, non-porous surface and sustainability, food grade silicone is also considered to provide a superior bacterial-free interface. Still further, the food-grade silicone has inherent antimicrobial properties in regard to both gram-positive and gram-negative microbial strains and fungi.
Shown and described herein is an improved Double Lock Sterile Entry IV Port and Syringe System 10, also referred to as a three-part interface, for positioning between a syringe 60 and an IV port (not shown) to provide a closed system for drawing up and injecting liquid drugs, shown in its assembled form in
The syringe interface 40 has a first end configured to receive the shrouded interface 62 and a second end to receive the cannula receiving extension 56. A threaded end 64 of the cannula receiving extension 56 extends beyond the syringe interface 40 to provide a leak proof attachment to a standard drug delivery syringe 60.
With reference to
In use, an end of the IV cannula interface 20, best shown in
In a preferred embodiment the double lock sterile entry IV port and syringe system 10 described above and shown in
To assemble the double lock sterile entry IV port and syringe System 10 the user assembly
At the conclusion of the transfer of the drug from the syringe to the IV port, the syringe and IV port are disconnected by a quick twist in the opposite direction. Pulling the IV port and syringe apart initiates the spring in the syringe interface to assist in the separation. The bung-penetrating cannula is then retracted, the silicone bung seal reseals, and the silicone diaphragm leaflets return to their original closed position protecting the sterile chamber so that the IV port and syringe can be disconnected and reconnected in a reusable fashion.
The present invention provides embodiments of double lock sterile entry IV port and syringe interface system for placement between a sterile entry IV port and a sterile entry syringe delivery mechanism that can be joined together as part of a fluid delivery system. Embodiments of the sterile entry IV ports and sterile entry syringe delivery mechanisms can include covers over the entry or exit points of the IV port and the syringe delivery mechanism such that the entry/exit point and all of the components behind the entry/exit point remain sterile. The movement of the covers can be caused by the application of force to a portion of the cover structure at a point spaced from the entry/exit point in order to avoid contamination of the entry/exit point. Thus, the necessity of swabbing or otherwise sterilizing the entry/exit point can be eliminated. In some embodiments the cover and movement system are reusable.
The silicone bung 22 and adjacent components create a tortuous flow path to minimize/prevent transfer of potential pathogens. The silicone bung is solid and provides a vacuum-tight seal along the fluid path. The silicone bung once penetrated by the needle/cannula allows fluid or drug to pass through the interface assembly. The silicone bung reseals (is self-sealing); as the needle is withdrawn the bung wipes the needle minimizing exposure to drug vapors and fluid leakage.
It is understood that when an element is referred to as being “on” another element, it can be directly on the other element or intervening elements may also be present. Furthermore, relative terms such as “inner”, “outer”, “upper”, “above”, “lower”, “beneath”, and “below”, and similar terms, may be used herein to describe a relationship of one element to another. Terms such as “higher”, “lower”, “wider”, “narrower”, and similar terms, may be used herein to describe relative relationships. It is understood that these terms are intended to encompass different locations and orientations in addition to the orientation depicted in the figures.
Although the terms a, first, second, etc., may be used herein to describe various elements, components, regions and/or sections, these elements, components, regions, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, or section from another. Thus, unless expressly stated otherwise, a first element, component, region, or section discussed below could be termed a second element, component, region, or section without departing from the teachings of the present invention.
Embodiments of the invention are described herein with reference to illustrations that are schematic illustrations. As such, the actual dimensions of elements can be different, and variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances are expected. Thus, the elements illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of the product and are not intended to limit the scope of the invention.
Although the present invention has been described in detail with reference to certain preferred configurations, assembly and use thereof, other versions or combinations of the disclosed embodiments are possible. Also, while the present invention is shown and describe as three sub-assemblies the product as delivered to the users can include one or more of the subassemblies assembled together or all of the subassemblies can be provide partially assembled or as a single interface unit for attachment to the Syringe and IV port. Therefore, the spirit and scope of the invention should not be limited to the versions described above or shown in the Figures.
